000			03577nam a22004455i 4500
001			978-1-59259-866-3
003			DE-He213
005			20161121230554.0
007			cr nn 008mamaa
008			100301s2005 xxu| s |||| 0|eng d
020			_a9781592598663 _9978-1-59259-866-3
024	7		_a10.1385/1592598668 _2doi
050		4	_aRC254-282
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a616.994 _223
245	1	0	_aCamptothecins in Cancer Therapy _h[electronic resource] / _cedited by Val R. Adams, Thomas G. Burke.
264		1	_aTotowa, NJ : _bHumana Press, _c2005.
300			_aXIII, 460 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aCancer Drug Discovery and Development
505	0		_aBiochemistry, Pharmacology, and Chemistry -- Mechanism of Action of Topoisomerase 1 Poisons -- Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage -- Inhibitors of Topoisomerase I Function -- Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors -- Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage -- Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs -- Mechanisms of Resistance to Camptothecins -- Recent Advances in Camptothecin Drug Design and Delivery Strategies -- Clinical Perspectives -- Clinical Experience With 9-Aminocamptothecin -- Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin) -- Irinotecan -- Clinical Experience With Topotecan -- The Clinical Development of Lurtotecan -- Preclinical and Clinical Development of Exatecan (DX-951f) -- Camptothecins in the Treatment of Primary Brain Tumors -- Camptothecins in the Treatment of Lung Cancer -- Use of Camptothecins in the Treatment of Leukemia and Related Disorders.
520			_aClinical interest in the camptothecins continues to expand even though this class of topoisomerase I inhibitors has been studied for almost 50 years, and two early generation members of the family have gained FDA approval. In Camptothecins in Cancer Therapy, leading clinicians and researchers critically review our current understanding of camptothecins, their shortcomings, and the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance. Authoritative and up-to-date, Camptothecins in Cancer Therapy provides a comprehensive summary of camptothecin research, as well as a much-needed guide to all the latest information on their optimal therapeutic applications.
650		0	_aMedicine.
650		0	_aOncology.
650	1	4	_aMedicine & Public Health.
650	2	4	_aOncology.
700	1		_aAdams, Val R. _eeditor.
700	1		_aBurke, Thomas G. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781588290274
830		0	_aCancer Drug Discovery and Development
856	4	0	_uhttp://dx.doi.org/10.1385/1592598668
912			_aZDB-2-SME
950			_aMedicine (Springer-11650)
999			_c500759 _d500759